These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 578293)

  • 1. Changes in pituitary hormones serum levels in bromocryptine-treated parkinsonian patients.
    Polleri A; Carolei A; Rolandi E; Masturzo P; Meco G; Agnoli A
    Neuropsychobiology; 1977; 3(1):42-8. PubMed ID: 578293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pituitary and adrenal function in normal women after treatment with Lergotrile mesylate.
    Rabinowitz D; McKenna TJ; Benveniste R
    Isr J Med Sci; 1978 Feb; 14(2):256-60. PubMed ID: 418023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma pituitary hormones in patients with Parkinson's disease treated with bromocriptine.
    Hyyppä MT; Långvik VA; Rinne UK
    J Neural Transm; 1978; 42(2):151-7. PubMed ID: 650205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormonal changes induced by bromocriptine (CB-154) at the early stage of treatment.
    Strauch G; Valcke JC; Mahoudeau JA; Bricaire H
    J Clin Endocrinol Metab; 1977 Mar; 44(3):588-90. PubMed ID: 576425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the dopamine agonist, lergotrile mesylate, on circulating anterior pituitary hormones in man.
    Thorner MO; Ryan SM; Wass JA; Jones A; Bouloux P; Williams S; Besser GM
    J Clin Endocrinol Metab; 1978 Aug; 47(2):372-8. PubMed ID: 45463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocrine aspects of bromocriptine therapy in Parkinsonism.
    Shaw KM; Lees AJ; Franks S; Daggett P; Thompson BD; Stern GM
    J Neural Transm; 1978; 43(2):153-60. PubMed ID: 104006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Neuroendocrine aspects of Parkinson's disease. Therapeutic/effect of a prolactin inhibitor].
    Agnoli A; Casacchia M; Carolei A; Meco G; Zamponi A; Ruggieri S
    Minerva Med; 1976 Nov; 67(53):. PubMed ID: 1036612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of bromocryptine on the secretion of thyrotropic hormone (TSH), prolactin (Pr), human growth hormone (HGH), thyroxine (T4) and triiodothyroxine (T3) in hypothyroidism.
    Felt V; Nedvdková J
    Horm Metab Res; 1977 Jul; 9(4):274-7. PubMed ID: 408253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian refractoriness to gonadotropins in cases of inappropriate lactation: restoration of ovarian function with bromocryptine.
    Mroueh AM; Siler-Khodr TM
    J Clin Endocrinol Metab; 1976 Dec; 43(6):1398-401. PubMed ID: 1036743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Serum prolactin, GH, TSH, LH, FSH in hypothalamo-pituitary diseases].
    Ogawa N; Yozai S; Miyoshi M; Takahara J; Ofuji T
    Horumon To Rinsho; 1975 Nov; 23(11):1133-7. PubMed ID: 1240031
    [No Abstract]   [Full Text] [Related]  

  • 11. Follicle-stimulating hormone- and alpha-subunit-secreting pituitary tumor treated with bromocriptine.
    Vance ML; Ridgway EC; Thorner MO
    J Clin Endocrinol Metab; 1985 Sep; 61(3):580-4. PubMed ID: 2410444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of dopaminergic tone in postmenopausal women: effects of piribedil on anterior pituitary hormones.
    De Marinis L; Mancini A; Calabrò F; Sciuto R; Fiumara C; Zuppi P; Saporosi A; Barini A; Menini E
    Horm Metab Res; 1991 Jan; 23(1):30-4. PubMed ID: 1849868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Letter: Growth-hormone response to bromocriptine in parkinsonism.
    Shaw KM; Lees AJ; Hayes S; Ross EJ; Stern GM; Thompson BD
    Lancet; 1976 Jan; 1(7952):194. PubMed ID: 54702
    [No Abstract]   [Full Text] [Related]  

  • 14. Neuroendocrine aberrations in women with functional hypothalamic amenorrhea.
    Berga SL; Mortola JF; Girton L; Suh B; Laughlin G; Pham P; Yen SS
    J Clin Endocrinol Metab; 1989 Feb; 68(2):301-8. PubMed ID: 2493024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pituitary function and the somatotrophic system in patients with idiopathic Parkinson's disease under chronic dopaminergic therapy.
    Schaefer S; Vogt T; Nowak T; Kann PH;
    J Neuroendocrinol; 2008 Jan; 20(1):104-9. PubMed ID: 18081558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of dopamine agonists and haloperidol on release of prolactin, thyroid stimulating hormone, growth hormone and luteinizing hormone in rats.
    Mueller GP; Simpkins J; Meites J; Moore KE
    Neuroendocrinology; 1976; 20(2):121-35. PubMed ID: 958594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of parkinson's disease with bromocriptine.
    Lieberman A; Kupersmith M; Estey E; Goldstein M
    N Engl J Med; 1976 Dec; 295(25):1400-4. PubMed ID: 989885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gonadotropin and alpha-subunit responses to chronic gonadotropin-releasing hormone analog administration in patients with glycoprotein hormone-secreting pituitary tumors.
    Klibanski A; Jameson JL; Biller BM; Crowley WF; Zervas NT; Rivier J; Vale WW; Bikkal H
    J Clin Endocrinol Metab; 1989 Jan; 68(1):81-6. PubMed ID: 2535852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypothalamic-pituitary function following bromocriptine therapy in patients with prolactinomas.
    Badawy SZ; Notman DD; Sunderlin FS; Springer JM; Streeten DH; Omar MM; Marshall LD
    J Reprod Med; 1982 Mar; 27(3):139-45. PubMed ID: 6806469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth hormone and changes in the secretion of thyrotropic hormone after thyrotropin-releasing hormone (TRH): ineffectiveness of dopaminergic stimulation.
    Felt V; Nedvídková J
    Endokrinologie; 1982 Oct; 80(2):201-6. PubMed ID: 6819130
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.